Patent · US Active

17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof

US12359201B2 · kind B2 · utility

0Cited by

34References

39Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Gregory Hinkle · Plymouth, US
Frederic Tremblay · Boston, US
Noura S. Abul-Husn · New York, US
Omri GOTTESMAN · Sierra Sky Park, US
Alexander Li · White Plains, US
Xiping Cheng · Millwood, US
Yurong Xin · Tarrytown, US
Jesper Gromada · Scarsdale, US
Frederick Dewey · Winchester, US
Aris Baras · Tarrytown, US
Alan Shuldiner · Columbia, US
Stuart Milstein · Cambridge, US

Key dates

Filing date	Mar 20, 2019
Grant date	Jul 15, 2025
Priority date	—
Expiry date	Mar 20, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/50
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the HSD17B 13 gene, as well as methods of inhibiting expression of HSD17B13, and methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, using such dsRNA compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.